Savara (NASDAQ:SVRA) will post its quarterly earnings results after the market closes on Wednesday, November 7th. Analysts expect Savara to post earnings of ($0.34) per share for the quarter.
Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, August 9th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.02). On average, analysts expect Savara to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of NASDAQ:SVRA traded up $0.38 during midday trading on Tuesday, reaching $9.64. The company’s stock had a trading volume of 400 shares, compared to its average volume of 123,597. The company has a market cap of $329.54 million, a P/E ratio of -5.38 and a beta of -0.06. The company has a quick ratio of 10.30, a current ratio of 10.30 and a debt-to-equity ratio of 0.16. Savara has a 1 year low of $8.41 and a 1 year high of $17.19.
In other Savara news, CFO David L. Lowrance sold 18,480 shares of the business’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $9.22, for a total transaction of $170,385.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.10% of the stock is currently owned by insiders.
A hedge fund recently raised its stake in Savara stock. Bank of New York Mellon Corp raised its position in shares of Savara Inc (NASDAQ:SVRA) by 187.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,986 shares of the company’s stock after acquiring an additional 48,218 shares during the period. Bank of New York Mellon Corp owned approximately 0.21% of Savara worth $838,000 at the end of the most recent reporting period. 41.84% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently commented on the company. Zacks Investment Research raised Savara from a “sell” rating to a “hold” rating in a research report on Thursday, October 11th. BidaskClub downgraded Savara from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Canaccord Genuity set a $25.00 price objective on Savara and gave the company a “buy” rating in a research report on Tuesday, August 14th. Roth Capital assumed coverage on Savara in a research report on Monday, August 13th. They issued a “neutral” rating and a $12.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Savara in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $26.80.
COPYRIGHT VIOLATION NOTICE: “Savara (SVRA) to Release Quarterly Earnings on Wednesday” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/06/savara-svra-to-release-quarterly-earnings-on-wednesday.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More: Moving Average (MA)
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.